◈ Nootpedia
Compact view
Research pass: medium Compound OPTIONAL-ADD MEDIUM

Niacinamide

Extended Research
◈ Extended Research ◈

Our depth — beyond the mirror

Deeper analysis, verdict reasoning, and per-archetype recommendations from our research team.

▸ Our verdict OPTIONAL-ADD MEDIUM

Cheap, exceptionally safe, and a genuine NAD+ precursor — but at supplemental doses (50-500 mg) the systemic NAD+ effect is real but modest and largely overlaps with what NMN/NR deliver. The "high-dose nootropic" 500-1500 mg/day protocol has scattered cognitive and skin/longevity case data but no large RCT. For Dylan, a low-dose B3 inclusion (50-100 mg) is reasonable insurance; the 1500 mg high-dose protocol is not justified by current evidence.

Research pass: medium
▸ Decision matrix by user profile Per-archetype
  • Dylan20-30, brain-priority, high cognitive workload (Dylan-archetype)
    OPTIONAL-ADD

    low. 100 mg/day as B3 insurance is fine. High-dose protocol not justified.

  • 30-50, executive maintenance
    OPTIONAL-ADD

    250-500 mg/day as part of a longevity NAD+ stack is reasonable.

  • 50+, mild cognitive decline
    STRONG-CANDIDATE

    for inclusion in a NAD+ longevity stack at 500-1000 mg/day, given NAD+ decline with age and Phase 2 AD signal.

  • Anxiety-prone
    M

    benefit; some users report mild calming at higher doses (uncertain mechanism).

  • High athletic load, tested status
    OPTIONAL-ADD

    Mitochondrial cofactor support is mechanistically helpful; not banned.

  • Sleep-disordered
    S

    anecdotal sleep-deepening reports at 500-1000 mg pre-bed; underpowered evidence.

  • Recovery-focused
    OPTIONAL-ADD

    Mitochondrial repair support post-injury is theoretically helpful.

  • Strength/anabolic-focused
    N

    not a performance-enhancing target.

  • Skin-cancer-prone, fair-skinned, sun-exposed
    STRONG-CANDIDATE

    ONTRAC chemoprevention is the strongest niacinamide indication.

▸ Subjective experience (deep)
  • 50-100 mg: nothing felt; pure B-vitamin coverage
  • 500 mg: very subtle warmth/relaxation in some users (not the niacin flush — different mechanism, possibly mild GABAergic effect at higher doses)
  • 1000-1500 mg: reports of better sleep depth, calmer evenings, improved skin texture over weeks. Modest but real for the high-dose protocol users.
  • No stimulant or pro-cognitive felt effect; this is a slow tissue-level effect, not a felt nootropic
▸ Tolerance + cycling deep dive
  • Tolerance buildup: Minimal — works at the cofactor level, no receptor downregulation expected
  • Recommended cycle: Daily, no cycling needed at standard doses. High-dose protocols sometimes use 5-on/2-off to ease methyl-donor demand.
  • Reset protocol if needed: Not applicable.
▸ Stacking deep dive

Synergistic with

  • NMN, NR: Same NAD+ pathway from different angles; some users stack all three at lower doses each. Not strictly necessary but logical.
  • Apigenin: CD38 inhibition (apigenin) + NAD+ supply (niacinamide) — Sinclair-lab-style NAD+ stack covering both supply and preservation.
  • B12, folate, methyl donors: Counterbalance methyl-group demand at high doses.
  • Resveratrol, pterostilbene: SIRT activator co-stack — speculative but logical.

Avoid stacking with

  • Carbidopa, isoniazid: Both interact with B6/B3 metabolism; clinically minor for niacinamide vs niacin.
  • Other high-dose flushing niacin: Redundant.

Neutral / safe co-administration

All V4 stack compounds; no clinically meaningful interactions.

▸ Drug interactions deep dive
  • Statins + niacin: Increased rhabdomyolysis risk — but niacin-specific (lipid pathway), not niacinamide.
  • Anticonvulsants (carbamazepine, primidone): May alter B-vitamin pharmacokinetics; clinically minor.
  • Diabetes meds: Monitor glucose at high niacinamide doses.
▸ Pharmacogenomics
  • NAMPT polymorphisms affect rate of NAM → NMN conversion, possibly affecting individual NAD+ response. Not actionable without testing.
  • MTHFR variants may amplify methyl-donor depletion at high doses.
▸ Sourcing deep dive
Path Vendor Cost Reliability Notes
OTC supplement NOW Foods / Solgar / Nutricost (Amazon, iHerb) $5-12 / 100-250 caps 500 mg High Well-standardized; pharmaceutical-grade USP material is the global standard
Bulk powder Bulk Supplements $10 / 250 g High For high-dose protocols where capsules become impractical
▸ Biomarkers to track (deep)
  • Baseline: ALT, AST, glucose, HbA1c, homocysteine if going high-dose
  • During use (>500 mg/day chronic): Liver panel quarterly, fasting glucose
  • Post-cycle: Not applicable
▸ Controversies / open debates Live debate
  • Whether high-dose nicotinamide ever matches NMN/NR for brain NAD+ specifically is unresolved — Trammell 2016 and several follow-ups suggest near-equivalence, but NMN/NR proponents argue brain BBB transport favors the intermediates. PK humans is messy because much of oral NMN/NR is broken to NAM anyway.
  • Long-term insulin sensitivity question — Mendelian randomization and some chronic-use cohorts hint at modest worsening of insulin sensitivity with chronic >1.5 g/day; clinically minor in healthy populations.
  • Whether the ONTRAC skin-cancer benefit will replicate in primary prevention (vs recurrence) is being tested in ONTRANS.
▸ Verdict change log
  • 2026-05-06 — Initial verdict: OPTIONAL-ADD medium confidence. Low-dose B3 coverage is fine; high-dose protocol not justified by current evidence for Dylan's profile.
▸ Open questions / gaps Open
  • Brain-NAD+ response in young healthy humans at supplemental NAM doses — barely studied
  • Does adding low-dose NAM to NMN/NR offer any benefit over either alone — unstudied
  • Long-term methylation status with chronic high-dose use in MTHFR-variant populations
▸ Sources (full, with our context)
Back to compact view